Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Acute Toxicity: dermal

Currently viewing:

Administrative data

Endpoint:
acute toxicity: dermal
Type of information:
migrated information: read-across from supporting substance (structural analogue or surrogate)
Adequacy of study:
key study
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
other: This study is classified as reliable without restriction because it is similar to OECD Test Guideline 402.

Data source

Reference
Reference Type:
study report
Title:
Unnamed
Year:
1986
Report date:
1986

Materials and methods

Test guideline
Qualifier:
equivalent or similar to guideline
Guideline:
OECD Guideline 402 (Acute Dermal Toxicity)
GLP compliance:
yes
Test type:
other:
Limit test:
yes

Test material

Constituent 1
Reference substance name:
Light paraffinic distillate solvent extract (CAS# 64742-05-8)
IUPAC Name:
Light paraffinic distillate solvent extract (CAS# 64742-05-8)
Details on test material:
Treated distillate aromatic extracts (TDAEs) are a further processing of distillate aromatic extracts (DAEs) in an attempt to reduce the amount of 3-7 ring PAC that is present. Since the treatment is mostly a selective reduction of PACs, the data from DAEs can serve as read across where treatment was insufficient and a significant amount of PACs still remain (≥ 3 wt% DMSO extractables as measured by IP-346). 

- Name of test material (as cited in study report): API 83-16, CAS No. 64742-05-8
- Physical state: liquid, brown

Test animals

Species:
rabbit
Strain:
New Zealand White
Sex:
male/female
Details on test animals or test system and environmental conditions:
TEST ANIMALS
- Source: Hazleton Dutchland, Inc., Denver, Pennsylvania

- Weight at study initiation: 2455 to 3134 grams
- Housing: maintained individually in screen-bottom cages
- Diet (e.g. ad libitum): Purina certified rabbit chow 5322, ad libitum
- Water (e.g. ad libitum): ad libitum
- Acclimation period: at least 14 days


ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20 to 24
- Humidity (%): 56 to 70
- Photoperiod (hrs dark / hrs light): 12/12

Administration / exposure

Type of coverage:
occlusive
Vehicle:
unchanged (no vehicle)
Details on dermal exposure:
TEST SITE
- Area of exposure: back, 2 male and 2 female rabbits in each dosage had their skin abraded
- % coverage: 10% of total body area
- Type of wrap if used: wrapped with an eight-ply gauze bandage and overwrapped with saran wrap and elastoplast tape


REMOVAL OF TEST SUBSTANCE
- Washing (if done): wiped clean with wet disposable paper towels
- Time after start of exposure: 24 hours


TEST MATERIAL
- Amount(s) applied (volume or weight with unit): 2000 to 3000 mg/kg body weight

Duration of exposure:
24 hours
Doses:
2000 mg/kg body weight, 3000 mg/kg body weight
No. of animals per sex per dose:
4
Control animals:
no
Details on study design:
- Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Observed for clinical signs and mortality hourly for the first 6 hours and then daily for dermal irritation and twice daily for clinical signs of mortality for a period of 14 days
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, body weight

Results and discussion

Effect levels
Sex:
male/female
Dose descriptor:
LD50
Effect level:
> 3 000 mg/kg bw
Mortality:
No mortality was observed in any of the 3000 mg/kg body weight dosage levels, one female with intact skin
Clinical signs:
other: At the 2000mg/kg bw dosage level: diarrhoea, dyspnoea, hypoactivity, prostration, emaciation, soft stool At the 3000mg/kg bw dosage level: no signs of systemic toxicity (or mortality) Dermal irritation was observed and ranged from slight to severe for ery

Applicant's summary and conclusion

Interpretation of results:
not classified
Remarks:
Migrated information LD50 > 3000 mg/kg body weight Criteria used for interpretation of results: EU
Conclusions:
The estimated dermal LD50 is greater than 3000 mg/kg body weight in males and females.
Executive summary:

Justification for Read Across

Treated distillate aromatic extracts (TDAEs) are a further processing of distillate aromatic extracts (DAEs) in an attempt to reduce the amount of 3-7 ring PAC that is present. Since the treatment is mostly a selective reduction of PACs, the data from DAEs can serve as read across where treatment was insufficient and a significant amount of PACs still remain (≥ 3 wt% DMSO extractables as measured by IP-346). Where treatment was sufficient to reduce the 3-7 ring PACs (<3 wt% DMSO extractables as measured by IP-346), the material is most similar to a lubricating base oil and it is this data that should be used for read across. 

In an acute dermal toxicity study, groups of New Zealand White rabbits (8/sex) were dermally exposed to undiluted light paraffinic distillate solvent extract for 24 hours to 10% of total body area at doses of 2000 and 3000 mg/kg bw. Animals then were observed for 14 days. For purposes of classification and labelling and registration under REACH aromatic extracts are sub-divided into the categories of untreated distillate aromatic extracts (DAE), treated distillate aromatic extracts (TDAE), and residual aromatic extracts (RAE). Some of the classifications are based on 3-7 ring PAC content, which is not substantively affected by whether the aromatic extract is derived from paraffinic or naphthenic or “light” or “heavy” crude.

Therefore, DAEs and TDAEs are not subclassified based on crude oil source or viscosity, i.e., for any health endpoint data from any one of the untreated DAEs can be “read-across” to the remaining DAEs and whole TDAE category.

 

At the 2000mg/kg bw dosage level: diarrhoea, dyspnoea, hypoactivity, prostration, emaciation, soft stool. At the 3000mg/kg bw dosage level: no signs of systemic toxicity (or mortality). Dermal irritation was observed and ranged from slight to severe for erythema and oedema. The dermal LD50 was determined to be greater than 3000 mg/kg body weight in both males and females. According to EU criteria, the test material is not classified.

 

This study received a Klimisch score of 1 and is classified as reliable without restriction because it is similar to OECD Test Guideline 402.